General Replicel/Shiseido News

Quote:

---

Originally Posted by hellouser

Hey Lacazette,

Is there anything you'd want to ask the guys at Replicel during the Hair Congress next month?

---

Hey Hellouser, I do'nt tking about something really particular, but maybe I would want to ask a confirmation that their protocol they are working on is suppose to lead to a high number of de novo hair follicles/ HF neogenesis or if it is more in their mind to save the current hair an miniaturized ones

US army researchers explained that DSC cells can lead to HF neogenesis like DP cells, but maybe it depend on the protocol power/amount of cells, or whatever, so to have a confirmation from them that they work on the real cure would be quite relaxing hehe

Also if Shiseido have changed/enhanced something in the protocol/type of cells they use, for the trial they will enter or if it is exactly the same of replicel phase 1

is there somewhere we can donateù? what's going on with that?

I think this answers our questions. Really good interview, that explains a lot. I'm cautiously optimistic after hearing this. https://www.baldtruthtalk.com/thread...ecord-Straight

Any updated on Replicel?

I have some shares of Replicel and periodically check in to see if there are any updates on their clinical trials and such. Even though the stock is taking a beating right now, the CEO put forth a statement some time ago that offers some clarity on a target date for release in Japan. Check it out:

"A company in transition. RepliCel is transitioning from an early-stage biotech company to one with commercial products.
Today we sit as an early-stage biotech company but one with a rapidly maturing and diversified portfolio of products in development characterized by:
three products in active clinical trials, two of which (RCT-01 & RCS-01) are anticipated to generate clinical data by year-end,
a medical device (RCI-02) in late-stage development which is on-track to be launched to the market in 2017, licensing discussion with major international companies are underway, and
a major international licensing and co-development partnership in place around a product being co-developed with that partner which has the potential to be on the market in Japan in 2018.
2016 promises to be an important year for RepliCel. Over the next 12-15 months, everything we've been working on over the past 36 months has material milestones including:
clinical data from both our RCT-01 (chronic tendon injury) and RCS-01 (aging and sub-damaged skin) clinical trials in late 2016,
Shiseido launching their next-phase clinical trial of RCH-01 (pattern baldness) in Japan in early 2016. This is expected to be approximately a 20-month trial and has the potential to lead to a market launch in 2018 in Japan, and
filing a CE mark application for our dermal injector (RCI-02) seeking permission to sell the device in Europe with label approval for injection of hyaluronic acid-based dermal fillers."

I have some shares of Replicel and periodically check in to see if there are any updates on their clinical trials and such. Even though the stock is taking a beating right now, the CEO put forth a statement some time ago that offers some clarity on a target date for release in Japan. Check it out:

"A company in transition. RepliCel is transitioning from an early-stage biotech company to one with commercial products.
Today we sit as an early-stage biotech company but one with a rapidly maturing and diversified portfolio of products in development characterized by:
three products in active clinical trials, two of which (RCT-01 & RCS-01) are anticipated to generate clinical data by year-end,
a medical device (RCI-02) in late-stage development which is on-track to be launched to the market in 2017, licensing discussion with major international companies are underway, and
a major international licensing and co-development partnership in place around a product being co-developed with that partner which has the potential to be on the market in Japan in 2018.
2016 promises to be an important year for RepliCel. Over the next 12-15 months, everything we've been working on over the past 36 months has material milestones including:
clinical data from both our RCT-01 (chronic tendon injury) and RCS-01 (aging and sub-damaged skin) clinical trials in late 2016,
Shiseido launching their next-phase clinical trial of RCH-01 (pattern baldness) in Japan in early 2016. This is expected to be approximately a 20-month trial and has the potential to lead to a market launch in 2018 in Japan, and
filing a CE mark application for our dermal injector (RCI-02) seeking permission to sell the device in Europe with label approval for injection of hyaluronic acid-based dermal fillers."

This is a good sign, right!?

Awesome :).

lol - i remember when Replicel said the treatment could be availabel mid 2015 in Japan, then they kept putting back the clinical trials, then eventually they abandoned them.

In a month it's going to be the middle of 2016 lol they need to get their crap together

1000 dollars for the treatment.